Standard

Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome. / Semenov, Konstantin N.; Prokopiev, Ilya A.; Petukhova, Natalya V.; Kremenetskaya, Uliana A.; Senichkina, Dina A.; Epifanovskaya, Olga S.; Rumiantsev, Andrei M.; Andoskin, Pavel A.; Rizaev, Jasur A.; Kholmurodova, Dilafruz K.; Ageev, Sergei V.; Anufrikov, Yurii A.; Zakharov, Egor E.; Moiseev, Ivan S.; Sharoyko, Vladimir V.

в: Journal of Molecular Liquids, Том 413, 125743, 01.11.2024.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Semenov, KN, Prokopiev, IA, Petukhova, NV, Kremenetskaya, UA, Senichkina, DA, Epifanovskaya, OS, Rumiantsev, AM, Andoskin, PA, Rizaev, JA, Kholmurodova, DK, Ageev, SV, Anufrikov, YA, Zakharov, EE, Moiseev, IS & Sharoyko, VV 2024, 'Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome', Journal of Molecular Liquids, Том. 413, 125743. https://doi.org/10.1016/j.molliq.2024.125743

APA

Semenov, K. N., Prokopiev, I. A., Petukhova, N. V., Kremenetskaya, U. A., Senichkina, D. A., Epifanovskaya, O. S., Rumiantsev, A. M., Andoskin, P. A., Rizaev, J. A., Kholmurodova, D. K., Ageev, S. V., Anufrikov, Y. A., Zakharov, E. E., Moiseev, I. S., & Sharoyko, V. V. (2024). Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome. Journal of Molecular Liquids, 413, [125743]. https://doi.org/10.1016/j.molliq.2024.125743

Vancouver

Semenov KN, Prokopiev IA, Petukhova NV, Kremenetskaya UA, Senichkina DA, Epifanovskaya OS и пр. Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome. Journal of Molecular Liquids. 2024 Нояб. 1;413. 125743. https://doi.org/10.1016/j.molliq.2024.125743

Author

Semenov, Konstantin N. ; Prokopiev, Ilya A. ; Petukhova, Natalya V. ; Kremenetskaya, Uliana A. ; Senichkina, Dina A. ; Epifanovskaya, Olga S. ; Rumiantsev, Andrei M. ; Andoskin, Pavel A. ; Rizaev, Jasur A. ; Kholmurodova, Dilafruz K. ; Ageev, Sergei V. ; Anufrikov, Yurii A. ; Zakharov, Egor E. ; Moiseev, Ivan S. ; Sharoyko, Vladimir V. / Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome. в: Journal of Molecular Liquids. 2024 ; Том 413.

BibTeX

@article{35d531a6a24348fd823cb3eaa6db4a63,
title = "Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome",
abstract = "This work is devoted to the study of biocompatibility, cyto- and genotoxicity, mechanism of action and prospects for the use of atranorin, which is an AKT kinase inhibitor, for the treatment of myelodysplastic syndrome. Atra- norin was isolated by preparative flash chromatography; identification was carried out by UV, IR, and NMR spec- troscopy, mass spectrometry, and elemental analysis. Biocompatibility studies included studies of haemocompat- ibility, genotoxicity, antioxidant activity, cytotoxicity against ECV340 and HEK293 cell lines. Computer model- ling of the interaction of atranorin with AKT kinase was carried out using docking followed by molecular dynam- ics of the resulting complexes; the ADMET properties of atranorin were also calculated. Flow cytometry included analysis of the expression level of PD-L1 and TIM-3 in the presence of atranorin on THP-1, Mono-Mac-1 and KG-1 cell lines, as well as human bone marrow cells.",
keywords = "Atranorin, Biocompatibility, Cytotoxicity, AKT kinase, Genotoxicity, Atranorin, Biocompatibility, Cytotoxicity, Genotoxicity, AKT kinase",
author = "Semenov, {Konstantin N.} and Prokopiev, {Ilya A.} and Petukhova, {Natalya V.} and Kremenetskaya, {Uliana A.} and Senichkina, {Dina A.} and Epifanovskaya, {Olga S.} and Rumiantsev, {Andrei M.} and Andoskin, {Pavel A.} and Rizaev, {Jasur A.} and Kholmurodova, {Dilafruz K.} and Ageev, {Sergei V.} and Anufrikov, {Yurii A.} and Zakharov, {Egor E.} and Moiseev, {Ivan S.} and Sharoyko, {Vladimir V.}",
year = "2024",
month = nov,
day = "1",
doi = "10.1016/j.molliq.2024.125743",
language = "English",
volume = "413",
journal = "Journal of Molecular Liquids",
issn = "0167-7322",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome

AU - Semenov, Konstantin N.

AU - Prokopiev, Ilya A.

AU - Petukhova, Natalya V.

AU - Kremenetskaya, Uliana A.

AU - Senichkina, Dina A.

AU - Epifanovskaya, Olga S.

AU - Rumiantsev, Andrei M.

AU - Andoskin, Pavel A.

AU - Rizaev, Jasur A.

AU - Kholmurodova, Dilafruz K.

AU - Ageev, Sergei V.

AU - Anufrikov, Yurii A.

AU - Zakharov, Egor E.

AU - Moiseev, Ivan S.

AU - Sharoyko, Vladimir V.

PY - 2024/11/1

Y1 - 2024/11/1

N2 - This work is devoted to the study of biocompatibility, cyto- and genotoxicity, mechanism of action and prospects for the use of atranorin, which is an AKT kinase inhibitor, for the treatment of myelodysplastic syndrome. Atra- norin was isolated by preparative flash chromatography; identification was carried out by UV, IR, and NMR spec- troscopy, mass spectrometry, and elemental analysis. Biocompatibility studies included studies of haemocompat- ibility, genotoxicity, antioxidant activity, cytotoxicity against ECV340 and HEK293 cell lines. Computer model- ling of the interaction of atranorin with AKT kinase was carried out using docking followed by molecular dynam- ics of the resulting complexes; the ADMET properties of atranorin were also calculated. Flow cytometry included analysis of the expression level of PD-L1 and TIM-3 in the presence of atranorin on THP-1, Mono-Mac-1 and KG-1 cell lines, as well as human bone marrow cells.

AB - This work is devoted to the study of biocompatibility, cyto- and genotoxicity, mechanism of action and prospects for the use of atranorin, which is an AKT kinase inhibitor, for the treatment of myelodysplastic syndrome. Atra- norin was isolated by preparative flash chromatography; identification was carried out by UV, IR, and NMR spec- troscopy, mass spectrometry, and elemental analysis. Biocompatibility studies included studies of haemocompat- ibility, genotoxicity, antioxidant activity, cytotoxicity against ECV340 and HEK293 cell lines. Computer model- ling of the interaction of atranorin with AKT kinase was carried out using docking followed by molecular dynam- ics of the resulting complexes; the ADMET properties of atranorin were also calculated. Flow cytometry included analysis of the expression level of PD-L1 and TIM-3 in the presence of atranorin on THP-1, Mono-Mac-1 and KG-1 cell lines, as well as human bone marrow cells.

KW - Atranorin

KW - Biocompatibility

KW - Cytotoxicity

KW - AKT kinase

KW - Genotoxicity

KW - Atranorin

KW - Biocompatibility

KW - Cytotoxicity

KW - Genotoxicity

KW - AKT kinase

U2 - 10.1016/j.molliq.2024.125743

DO - 10.1016/j.molliq.2024.125743

M3 - Article

VL - 413

JO - Journal of Molecular Liquids

JF - Journal of Molecular Liquids

SN - 0167-7322

M1 - 125743

ER -

ID: 123590383